You are here

  • Home
  • Online First
  • Patterns of care and outcomes for women with uterine cancer and ovarian metastases

Article Text

Article menu

other Versions

Download PDFPDF
Original Article
Patterns of care and outcomes for women with uterine cancer and ovarian metastases
  1. Nathaniel L Jones1,2,
  2. Yongmei Huang1,
  3. Sudeshna Chatterjee1,2,
  4. Ana I Tergas1,2,3,4,
  5. William M Burke1,2,4,
  6. June Y Hou1,2,4,
  7. Israel Deutsch1,2,4,
  8. Cande V Ananth1,3,
  9. Alfred I Neugut1,2,3,4,
  10. Dawn L Hershman1,2,3,4 and
  11. Jason D Wright1,2,4
  1. 1 Columbia University College of Physicians and Surgeons, New York City, New York, USA
  2. 2 New York Presbyterian Hospital, New York City, New York, USA
  3. 3 Mailman School of Public Health, Columbia University, New York City, New York, USA
  4. 4 Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, New York City, New York, USA
  1. Correspondence to Jason D Wright, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA; jw2459{at}columbia.edu

Abstract

Objective For women with uterine cancer with metastases isolated to the adnexa (stage IIIA) optimal adjuvant therapy is unknown. We performed a population-based analysis to examine the use of chemotherapy, vaginal brachytherapy, and external beam therapy (in women with stage IIIA uterine cancer.

Methods The National Cancer Database was used to identify women with stage IIIA uterine cancer with ovarian metastasis from 2004 to 2012. We explored the use of chemotherapy, vaginal brachytherapy, and external beam therapy over time. Multivariable models were developed to examine factors associated with survival.

Results We identified 4088 women with uterine cancer and ovarian metastases. Overall, 56.2% of women received chemotherapy. Vaginal brachytherapy was used in 11.1%, while 36.6% received external beam therapy. Five-year survival was 64.7 % (95% CI, 62.9% to 66.5%). In a multivariable model, chemotherapy was associated with a 38% decrease in mortality (HR = 0.62; 95% CI, 0.54 to 0.71). Similarly, both external beam therapy (HR = 0.74; 95% CI, 0.65 to 0.85) and vaginal brachytherapy (HR = 0.67; 95% CI, 0.53 to 0.85) were associated with improved survival. When the cohort was limited to women who received chemotherapy, radiation was associated with improved overall survival (HR 0.74, 95% CI 0.61 to 0.90). There was no difference in survival between the use of external beam therapy and vaginal brachytherapy.

Conclusions Chemotherapy was associated with a decrease in mortality in women with endometrial cancer and ovarian metastases. The addition of radiation therapy was associated with improved overall survival, although there was no difference between external beam therapy and vaginal brachytherapy.

https://doi.org/10.1136/ijgc-2018-000047

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests JDW has served as a consultant for Tesaro and Clovis Oncology. AIN has served as a consultant to Pfizer, Teva, Otsuka, and United Biosource Corporation. He is on the medical advisory board of EHE, Intl. Dr. Wright (NCI R01CA169121-01A1) and DLH (NCI R01 CA166084) are recipients of grants from the National Cancer Institute. DLH is the recipient of a grant from the Breast Cancer Research Foundation/Conquer Cancer Foundation.

    • Patient consent Not required.

    • Provenance and peer review Not commissioned; externally peer reviewed.